全身炎症性关节炎中的心血管风险
Cardiovascular Risk in Systemic Inflammatory Arthritis.
作者信息
Atzeni Fabiola, Alciati Alessandra
机构信息
Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, 98122 Messina, Italy.
Department of Clinical Neurosciences, Villa S. Benedetto Menni, 22032 Albese con Cassano, Italy.
出版信息
J Clin Med. 2023 Apr 8;12(8):2779. doi: 10.3390/jcm12082779.
Abstract
In recent years, several papers have been published on cardiovascular (CV) involvement, risk, management, and treatment in systemic inflammatory arthritis (SIA), including rheumatoid arthritis, (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) [...].
摘要
近年来，已有多篇关于系统性炎性关节炎（SIA），包括类风湿关节炎（RA）、银屑病关节炎（PsA）和中轴型脊柱关节炎（axSpA）的心血管（CV）受累、风险、管理及治疗的论文发表[……]
相似文献
1
Cardiovascular Risk in Systemic Inflammatory Arthritis.全身炎症性关节炎中的心血管风险
J Clin Med. 2023 Apr 8;12(8):2779. doi: 10.3390/jcm12082779.
2
Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.类风湿关节炎、脊柱关节炎、银屑病关节炎和银屑病的生物制剂和新型免疫调节剂的药物生存情况——来自 DANBIO 和 DERMBIO 登记处的全国性队列研究。
Semin Arthritis Rheum. 2022 Apr;53:151979. doi: 10.1016/j.semarthrit.2022.151979. Epub 2022 Feb 9.
3
Psoriatic arthritis, axial spondyloarthritis and rheumatoid arthritis in Norway: nationwide prevalence and use of biologic agents.挪威的银屑病关节炎、中轴型脊柱关节炎和类风湿关节炎：全国患病率和生物制剂的使用情况。
Scand J Rheumatol. 2023 Jan;52(1):42-50. doi: 10.1080/03009742.2021.1997436. Epub 2022 Jan 11.
4
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis.血清钙卫蛋白：类风湿关节炎和中轴型脊柱关节炎有前景的生物标志物。
Arthritis Res Ther. 2020 May 6;22(1):105. doi: 10.1186/s13075-020-02190-3.
5
High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.与类风湿关节炎和中轴型脊柱关节炎患者相比，银屑病关节炎患者在接受 bDMARD 间隔治疗后疾病复发率较高：BIOPURE 登记处的真实数据。
Clin Rheumatol. 2021 Sep;40(9):3659-3665. doi: 10.1007/s10067-021-05728-1. Epub 2021 Apr 16.
6
Pain catastrophizing in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: biopsychosocial perspective and impact on health-related quality of life.类风湿关节炎、银屑病关节炎和轴性脊柱关节炎中的疼痛灾难化：生物心理社会视角及其对健康相关生活质量的影响
Rheumatol Int. 2022 Apr;42(4):669-682. doi: 10.1007/s00296-021-05070-4. Epub 2022 Jan 31.
7
Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark.类风湿关节炎、中轴型脊柱关节炎和银屑病关节炎女性患者子痫前期风险及疾病活动度和抗风湿治疗的影响：来自瑞典和丹麦的协作匹配队列研究。
RMD Open. 2022 Nov;8(2). doi: 10.1136/rmdopen-2022-002445.
8
All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study.类风湿关节炎、银屑病关节炎和中轴型脊柱关节炎的全因和病因特异性死亡率：一项全国性登记研究。
Rheumatology (Oxford). 2022 Nov 28;61(12):4656-4666. doi: 10.1093/rheumatology/keac210.
9
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.司库奇尤单抗对传统心血管危险因素和炎症生物标志物的影响：三项适应症汇总数据的事后分析
Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19.
10
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.戈利木单抗作为意大利类风湿关节炎、银屑病关节炎和中轴型脊柱关节炎患者的第二种抗TNFα药物的有效性：GO-BEYOND，一项前瞻性真实世界观察性研究。
J Clin Med. 2022 Jul 19;11(14):4178. doi: 10.3390/jcm11144178.
引用本文的文献
1
The genesis of cardiovascular risk in inflammatory arthritis: insights into glycocalyx shedding, endothelial dysfunction, and atherosclerosis initiation.炎症性关节炎中心血管风险的发生机制：糖萼脱落、内皮功能障碍与动脉粥样硬化形成的相关见解。
Clin Rheumatol. 2023 Oct;42(10):2541-2555. doi: 10.1007/s10067-023-06738-x. Epub 2023 Aug 15.
本文引用的文献
1
Diagnosis and management of cardiovascular risk in rheumatoid arthritis: main challenges and research agenda.
Expert Rev Clin Immunol. 2023 Mar;19(3):279-292. doi: 10.1080/1744666X.2023.2170351. Epub 2023 Feb 3.
2
Effects of Antirheumatic Treatment on Cell Cholesterol Efflux and Loading Capacity of Serum Lipoproteins in Spondylarthropathies.抗风湿治疗对脊柱关节病患者细胞胆固醇流出及血清脂蛋白载脂能力的影响
J Clin Med. 2022 Dec 9;11(24):7330. doi: 10.3390/jcm11247330.
3
Cardiovascular Risk Factors before Onset of Rheumatoid Arthritis Are Associated with Cardiovascular Events after Disease Onset: A Case-Control Study.类风湿关节炎发病前的心血管危险因素与疾病发病后的心血管事件相关：一项病例对照研究。
J Clin Med. 2022 Nov 3;11(21):6535. doi: 10.3390/jcm11216535.
4
The cardiometabolic conditions of psoriatic disease.银屑病的心血代谢状况。
Front Immunol. 2022 Sep 8;13:970371. doi: 10.3389/fimmu.2022.970371. eCollection 2022.
5
C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.C-反应蛋白与类风湿关节炎患者 10 年心血管风险。
Eur J Intern Med. 2022 Oct;104:49-54. doi: 10.1016/j.ejim.2022.07.001. Epub 2022 Jul 9.
6
Cardiovascular Morbidity in Ankylosing Spondylitis: A Focus on Inflammatory Cardiac Disease.强直性脊柱炎中的心血管疾病发病率：聚焦于炎症性心脏病
Cureus. 2022 Jun 3;14(6):e25633. doi: 10.7759/cureus.25633. eCollection 2022 Jun.
7
Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022.2022年类风湿关节炎患者的心血管疾病风险
J Clin Med. 2022 May 11;11(10):2704. doi: 10.3390/jcm11102704.
8
Associations of IL-18 with Altered Cardiovascular Risk Profile in Psoriatic Arthritis and Ankylosing Spondylitis.白细胞介素-18与银屑病关节炎和强直性脊柱炎患者心血管风险特征改变的相关性
J Clin Med. 2022 Jan 30;11(3):766. doi: 10.3390/jcm11030766.
9
Subclinical Atherosclerosis Measure by Carotid Ultrasound and Inflammatory Activity in Patients with Rheumatoid Arthritis and Spondylarthritis.通过颈动脉超声测量类风湿关节炎和脊柱关节炎患者的亚临床动脉粥样硬化及炎症活性
J Clin Med. 2022 Jan 27;11(3):662. doi: 10.3390/jcm11030662.
10
Cardiovascular effects of approved drugs for rheumatoid arthritis.类风湿关节炎治疗药物的心血管效应
Nat Rev Rheumatol. 2021 May;17(5):270-290. doi: 10.1038/s41584-021-00593-3. Epub 2021 Apr 8.
Zotero 插件